Literature DB >> 25774187

7, 8-dihydroxycoumarin improves neurological function in a mouse model of sciatic nerve injury.

Jianshi Du1, Qing Zhao2, Yingli Zhang2, Yu Wang2, Ming Ma2.   

Abstract

In the present study, a mouse model of sciatic nerve injury was treated with intraperitoneal injection of 7, 8-dihydroxycoumarin (10, 5, or 2.5 mg/kg per day). Western blot and real-time PCR results showed that growth associated protein 43 expression was significantly increased in the L4-6 segments of the spinal cord. The amplitude and velocity of motor nerve conduction in the sciatic nerve were significantly increased in model mice. In addition, the appearance of the myelin sheath in the injured sciatic nerve was regular, with an even thickness and clear outline, and the surrounding fibroplasia was not obvious. Our results indicate that 7, 8-dihydroxycoumarin can promote the repair of injured nerve by upregulating growth associated protein 43 expression in the corresponding spinal cord segments of mice with sciatic nerve injury.

Entities:  

Keywords:  7; 8-dihydroxycoumarin; growth associated protein 43; neural regeneration; peripheral nerve injury; sciatic nerve

Year:  2012        PMID: 25774187      PMCID: PMC4350131          DOI: 10.3969/j.issn.1673-5374.2012.06.007

Source DB:  PubMed          Journal:  Neural Regen Res        ISSN: 1673-5374            Impact factor:   5.135


INTRODUCTION

After cerebral ischemia/reperfusion in rats, growth associated protein 43 (GAP-43) expression gradually increased in the ischemic hemisphere, indicating the repairing effects of GAP-43 in nerve injury[123]. A previous study indicated that 7, 8-dihydroxycoumarin, an effective monomer isolated from thymelaeceae, can protect the cardiovascular system and permeate the blood-brain barrier[4]. 7, 8-dihydroxycoumarin can increase GAP-43 expression in ischemia/reperfusion regions in the early stage after ischemia and play a positive role in neuronal function recovery by removing necrotic substances, improving the water-electrolyte balance, enhancing neurotransmitter and energy metabolism, and secreting neurotrophic factors[456]. However, the effects of 7, 8-dihydroxycoumarin treatment on peripheral nerve regeneration remains poorly understood. The present study used a BALB/c mouse model of sciatic nerve injury to investigate the role of 7, 8-dihydroxycoumarin in peripheral nerve regeneration and functional recovery.

RESULTS

Quantitative analysis of experimental animals

A total of 169 BALB/c mice were studied. Nine died due to anesthetic accidents, while the remaining mice were used to establish models of unilateral sciatic nerve injury. The model mice were randomly assigned to injury or high, medium or low dose 7, 8-dihydroxycoumarin groups, with 40 animals in each group. The mice were intraperitoneally injected with 1 mL per day normal saline, or 10, 5 or 2.5 mg/kg per day 7, 8-dihydroxycoumarin, respectively. Totally 160 mice were included in the final analysis.

7, 8-dihydroxycoumarin upregulated GAP-43 protein expression in the L4-6 segments of the injured side in mice with sciatic nerve injury

Western blot detection showed that GAP-43 reached peak levels at 1 week after injury, which gradually decreased after 1 week, and finally decreased to normal levels at 2 weeks[78910]. High, medium and low dose 7, 8-dihydroxycoumarin increased GAP-43 protein expression in the L4-6 segments compared with the injury group (P < 0.05; Figure 1). GAP-43 protein expression was greater in the high and medium dose 7, 8-dihydroxycoumarin groups compared with low dose 7, 8-dihydroxycoumarin except for the high dose 7, 8-dihydroxycoumarin group at 8 weeks (P < 0.05; Table 1).
Figure 1

Growth associated protein 43 (GAP-43) expression in the L4-6 segments of mice with sciatic nerve injury. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

High (A), medium (B) and low (C) dose 7, 8- dihydroxycoumarin increased GAP-43 protein expression in the L4-6 segments compared with the injury group (D).

Table 1

Growth associated protein 43 (GAP-43) expres-sion in the L4-6 segments of mice with sciatic nerve injury treated with 7, 8-dihydroxycoumarin (Western blot)

Growth associated protein 43 (GAP-43) expression in the L4-6 segments of mice with sciatic nerve injury. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase. High (A), medium (B) and low (C) dose 7, 8- dihydroxycoumarin increased GAP-43 protein expression in the L4-6 segments compared with the injury group (D). Growth associated protein 43 (GAP-43) expres-sion in the L4-6 segments of mice with sciatic nerve injury treated with 7, 8-dihydroxycoumarin (Western blot)

7, 8-dihydroxycoumarin upregulated GAP-43 mRNA expression in the L4-6 segments of the injured side in mice with sciatic nerve injury

There was only a small amount of GAP-43 mRNA in the corresponding spinal cord segments of sciatic nerve in normal Balb/c mice[101112131415]. Real-time PCR results in this study showed that the GAP-43 mRNA level increased in the corresponding spinal cord segments after sciatic nerve injury. Also, the GAP-43 mRNA level was significantly greater in the high dose 7, 8-dihydroxycoumarin group compared with the medium and low dose 7, 8-dihydroxycoumarin groups at 1, 2 and 4 weeks after injury (P < 0.05; Figure 2).
Figure 2

Relative quantity of growth associated protein 43 (GAP-43) mRNA expression 1 to 8 weeks after sciatic nerve injury in mice treated with 7, 8-dihydroxycoumarin. aP < 0.05, bP < 0.01, vs. injury group. The results are expressed as the mean ± SD of 10 mice in each group. Intergroup differences were compared using one way analysis of variances and two-sample t-tests.

Relative quantity of growth associated protein 43 (GAP-43) mRNA expression 1 to 8 weeks after sciatic nerve injury in mice treated with 7, 8-dihydroxycoumarin. aP < 0.05, bP < 0.01, vs. injury group. The results are expressed as the mean ± SD of 10 mice in each group. Intergroup differences were compared using one way analysis of variances and two-sample t-tests.

7, 8-dihydroxycoumarin promoted neurological function in mice with sciatic nerve injury

Electrophysiological detection showed that high and medium dose 7, 8-dihydroxycoumarin increased the amplitude and velocity of motor nerve conduction in the sciatic nerve at 1, 2, 4, and 8 weeks after injury (P < 0.05), but low dose 7, 8-dihydroxycoumarin did not (Tables 2, 3).
Table 2

The amplitude of motor nerve conduction in mice with sciatic nerve injury (mV) treated with 7, 8-dihydroxycoumarin (neuroelectrophysiology method)

Table 3

The velocity of motor nerve conduction in mice with sciatic nerve injury (m/s) treated with 7, 8-dihydroxycoumarin

The amplitude of motor nerve conduction in mice with sciatic nerve injury (mV) treated with 7, 8-dihydroxycoumarin (neuroelectrophysiology method) The velocity of motor nerve conduction in mice with sciatic nerve injury (m/s) treated with 7, 8-dihydroxycoumarin

7, 8-dihydroxycoumarin improved the histological changes in the injured region in mice with sciatic nerve injury

Luxol fast blue staining showed that at 8 weeks after injury, the appearance of the myelin sheath in the injured sciatic nerve was regular, with an even thickness and clear outline, and the surrounding fibroplasias was not obvious in the high and medium dose 7, 8-dihydroxycoumarin groups. In the low dose 7, 8-dihydroxycoumarin group, the appearance and thickness of the myelin sheath was irregular, but the outline was clear, and fibrous connective tissue hyperplasy was observed. In the injury group, the appearance of the myelin sheath was irregular and fibrous connective tissue hyperplasy was observed (Figure 3).
Figure 3

The morphology of sciatic nerve samples in the injured side of mice in high (A), medium (B), low (C) dose 7, 8-dihydroxycoumarin, and injury groups (D) at 8 weeks after injury (Luxol fast blue staining, × 40).

The number of myelinated nerves differed in each group, which corresponded to a variety of color intensities. Arrows represented myelin sheath, and the axons did not stain.

The morphology of sciatic nerve samples in the injured side of mice in high (A), medium (B), low (C) dose 7, 8-dihydroxycoumarin, and injury groups (D) at 8 weeks after injury (Luxol fast blue staining, × 40). The number of myelinated nerves differed in each group, which corresponded to a variety of color intensities. Arrows represented myelin sheath, and the axons did not stain. At 8 weeks after injury, the number and diameter of myelinated nerve fibers in the injured region of sciatic nerve was greater in the high and medium dose 7, 8-dihydroxycoumarin groups compared with the low dose 7, 8-dihydroxycoumarin and injury groups (P < 0.05; Table 4).
Table 4

The number and diameter of myelinated nerve fibers in the injured region of the sciatic nerve of each group

The number and diameter of myelinated nerve fibers in the injured region of the sciatic nerve of each group

DISCUSSION

Natural drugs exhibit particular advantages in neural regeneration. In previous studies, 7, 8-dihydroxycoumarin has been used for brain nerve and nerve recovery after cerebral ischemia/reperfusion injury[161718]. Western blot and real-time PCR in the present study showed that high and medium dose 7, 8-dihydroxycoumarin significantly increased GAP-43 expression compared with the low dose 7, 8-dihydroxycoumarin and injury groups, and the increased GAP-43 expression was maintained for up to 2 weeks. GAP-43 protein and mRNA expressions increased in the L4-6 segments, Luxol fast blue staining of the myelin sheath demonstrated improvements and the electrophysiological index exhibited consistent change tendency with 7, 8-dihydroxycoumarin treatment. We conclude that 7, 8-dihydroxycoumarin promotes GAP-43 activation in the spinal cord anterior horn to regulate functional recovery after peripheral nerve injury[1415]. GAP-43 protein expression is a sensitive and specific biochemical marker of central lesions. GAP-43 expression in a certain range can promote nerve recovery and regeneration, and overexpression can inhibit inflammation and scar formation[1920212223242526272829]. In the present study, high and medium dose 7, 8-dihydroxycoumarin significantly increased GAP-43 expression. Furthermore Luxol fast blue staining of the myelin sheath and electrophysiological examination indicate high and medium dose 7, 8-dihydroxycoumarin promoted nerve recovery and regeneration. These results suggest high and medium dose 7, 8-dihydroxycoumarin promote GAP-43 expression in an appropriate range[78910] and regulate peripheral nerve generation. In conclusion, 7, 8-dihydroxycoumarin can improve functional recovery of mice with sciatic nerve injury.

MATERIALS AND METHODS

Design

A randomized, controlled, animal experiment.

Time and setting

The experiment was performed at the National Key Laboratory of China-Japan Union Hospital, Jilin University, China from November 2010 to May 2011.

Materials

Animals

A total of 160 healthy, adult, male BALB/c mice, aged 8 weeks, weighing 20 ± 2 g, were provided by the Laboratory Animal Center of the College of Basic Medicine, Jilin University (No. SCXK(Ji)2007-0001). Experimental procedures were performed in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals issued by the Ministry of Science and Technology of China[30].

Drugs

Daphnetin (95.5% 7, 8-dihydroxycoumarin) was provided by Jilin Xidian Pharmaceutical Technology Development, China. Daphnetin samples were identified using high performance liquid chromatography[31]. The relative molecular mass was 178.141 5 and the chemical structural formula was as follows: The daphnetin powder was weighed on an analytical balance (Shanghai Keda Instrument Factory) and dissolved in normal saline. The 7, 8-dihydroxycoumarin solution was filtered through a 0.02 mm micropore membrane and stored at -20°C. The 7, 8-dihydroxycoumarin solution prepared and stored in this manner is stable for 1 month.

Methods

Establishment of the sciatic nerve injury model

The mice were anesthetized by intraperitoneal injection of 1% penthiobarbital sodium (100 mg/kg) and fixed in the prone position. A 2 cm longitudinal incision was made at the posterior femur of the hind limb at the injured side, and the sciatic nerve was exposed. The sciatic nerve trunk and surrounding tissues were isolated. The sciatic nerve at 0.5 cm below ischial tuberosity was completely excised. The sciatic nerve was anastomosed using a 11/0 micro suture under a 12 × magnification microscope (Zhenjiang Surgical Microinstrument Factory, Jiangsu, China), and the muscle and skin were sutured layer by layer[29] (Figure 4). Successful models were demonstrated by nerve end-to-end anastomosis and smooth anastomotic stoma.
Figure 4

The establishment of the sciatic nerve injury model. The arrow represents the end-to-end anastomosis of excised nerves.

The establishment of the sciatic nerve injury model. The arrow represents the end-to-end anastomosis of excised nerves.

Intervention

The clinically used dose of 7, 8-dihydroxycoumarin was converted into a comparable dose for intraperitoneal injection in mice[32], and was labeled as the medium dose of 7, 8-dihydroxycoumarin in the present study. The high, medium and low dose 7, 8-dihydroxycoumarin and injury groups were respectively intraperitoneally injected with 10, 5 or 2.5 mg/kg reconstituted in 1 mL aliquots per day 7, 8-dihydroxycoumarin[32] or 1 mL per day normal saline, immediately after injury. The administration was not terminated until sampling.

Sampling

At 1, 2, 4 and 8 weeks after injury, 10 mice were selected from each group and anesthetized by intraperitoneal injection of 1% pentobarbital sodium (100 mg/kg). The vertebral canal was opened using gouge forceps through the median incision at the posterior vertebral column to expose and dissociate the L4-6 segments connected with the injured sciatic nerve (Figure 5). The spinal cord at the L4-6 segments of the injured side was harvested, placed in a marked frozen tube, and immersed in liquid nitrogen for Western blot and real-time PCR. In addition, the nerve trunk, 0.5 cm distal to the anastomotic stoma (including the stoma) was harvested, fixed in 10% neutral formalin for over 72 hours, dehydrated with gradient alcohol, paraffin embedded, and sectioned (2 μm thick).
Figure 5

The samples of the L4-6 segments of the spinal cord. The arrow represents the lumbar intumescentia of L4-6.

The samples of the L4-6 segments of the spinal cord. The arrow represents the lumbar intumescentia of L4-6.

Western blot for GAP-43 protein expression in the L4-6 segments of the injured side in mice with sciatic nerve injury

The spinal cord tissues were rapidly harvested from liquid nitrogen and ground by a mortar. These tissue fragments were mixed with radio-immunoprecipitation assay lysis buffer to extract the protein, then loading buffer was added, followed by boiling for 15 minutes. After centrifugation, the supernatant was harvested for 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. The protein was transferred to a polyvinylidene difluoride membrane. The membrane was soaked in a rabbit anti-mouse GAP-43 monoclonal antibody (1: 1 000; Roche, Nutley, NJ, USA) overnight at 4°C and washed with 0.01 M PBS for 5 minutes 4 times. The membrane was then immersed in a goat anti-rabbit IgG antibody (1:10 000; Roche) at room temperature for 1 hour and then washed with 0.01 M PBS for 5 minutes 4 times, followed by enhanced chemiluminescence (Roche). The bands were scanned and analyzed. A gel imaging system (Alpha-Innotech, San Leandro, CA, USA) was used for absorbance analysis, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) serving as an internal reference. The absorbance ratio of the target band to GAPDH was measured. A high ratio indicates strong protein expression.

Real-time PCR for GAP-43 mRNA expression in L4-6 segments of the injured side in mice with sciatic nerve injury

Primers were designed using Beacon designer 7 software (Premier Biosoft, California, USA). Specificity was verified using the Blast test (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Spinal cord tissues of L4-6 segments at each time point were harvested. Total RNA was extracted using the TRIzol reagent (Shanghai Sangon, Shanghai, China). RNA was reverse-transcribed into cDNA. With cDNA as template, GAP-43 at L4-6 segments was amplified by PCR. One pair of GAPDH primers was added in every reaction system and used as an internal reference. The amplification conditions were 40 cycles of 95°C for 30 seconds, 58°C for 60 seconds and 72°C for 60 seconds. The threshold cycle value of the target gene and the internal reference gene was determined and used to quantify the target gene and plot histogram (SigmaPlot 8.0, Bio-Rad, Hercules, CA, USA).

Myelin sheath luxol fast blue staining for neural regeneration after sciatic nerve injury

The nerve trunk, 0.5 cm distal to the anastomotic stoma (including the stoma) was harvested. Then the nerve trunk was fixed in 10% neutral formalin for over 72 hours, dehydrated with gradient alcohol, paraffin embedded, and sectioned for hematoxylin-eosin staining to observe structures, cell proliferation, and inflammatory cell infiltration. After dewaxing, the sections were immersed in luxol fast blue solution at 60°C for 12 hours, mixed with 95% alcohol for 5 minutes, treated with 0.05% lithium carbonate for 15 seconds, washed with 70% alcohol and distilled water, dehydrated, cleared and mounted. The sections were observed by light microscopy (Olympus, Tokyo, Japan) and the number of axons and the diameter stained by lithium carbonate were determined by an image scanner (40 ×, Olympus).

Nerve action potential conduction velocity of the injured side in mice with sciatic nerve injury

The injured sciatic nerve was detected at 1, 2, 4, and 8 weeks after injury using a Medtronic Keypoint myoelectricity/evoked potential system (Medtronic, Minneapolis, Minnesota, USA). Briefly, the room temperature was maintained at 24°C. The mice were anesthetized by intraperitoneal injection of 1% pentobarbital sodium, sterilized, and placed in a prone position. The sciatic nerve was exposed. A concentric needle electrode was punctured into the soleus muscle as the recording electrode (M point), and the ground electrode was placed in the tail. Parallel stimulating electrodes (with a 2 mm gap) were respectively placed at the ischial tuberosity proximal to the anastomotic stoma of the injured nerve (P point) and the bifurcation of the distal sciatic nerve (D point). The mice were stimulated with a 10 mA current. The interelectrode distance of stimulating electrodes was measured using a Vernier caliper and motor nerve conduction velocity was calculated as tge: interelectrode distance/difference in action potential latency (duration that the nerve impulse passed through two points, i.e. the motor conduction velocity between two points). The amplitude of the action potential was detected using a Vernier caliper.

Statistical analysis

The data were expressed as the mean ± SD and analyzed using the SPSS 17.0 software (SPSS, Chicago, IL, USA). The differences in the mean value between groups were compared using a one way analysis of variance; paired comparisons of the mean value between groups were performed using a two-sample t-test.
  24 in total

1.  Increase of the RNA-binding protein HuD and posttranscriptional up-regulation of the GAP-43 gene during spatial memory.

Authors:  Alessia Pascale; Pavel A Gusev; Marialaura Amadio; Tania Dottorini; Stefano Govoni; Daniel L Alkon; Alessandro Quattrone
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

2.  Corticospinal neurons up-regulate a range of growth-associated genes following intracortical, but not spinal, axotomy.

Authors:  M R J Mason; A R Lieberman; P N Anderson
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

3.  GAP-43 transgenic mice: dispersed genomic sequences confer a GAP-43-like expression pattern during development and regeneration.

Authors:  J Vanselow; E Grabczyk; J Ping; M Baetscher; S Teng; M C Fishman
Journal:  J Neurosci       Date:  1994-02       Impact factor: 6.167

4.  Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins.

Authors:  S L Eastwood; P J Harrison
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

5.  Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1.

Authors:  M S Chen; A B Huber; M E van der Haar; M Frank; L Schnell; A A Spillmann; F Christ; M E Schwab
Journal:  Nature       Date:  2000-01-27       Impact factor: 49.962

6.  Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor.

Authors:  E B Yang; Y N Zhao; K Zhang; P Mack
Journal:  Biochem Biophys Res Commun       Date:  1999-07-14       Impact factor: 3.575

7.  Expression of GAP-43 during development and after monocular enucleation in the rat superior colliculus.

Authors:  Henrique Rocha Mendonça; Sheila Espírito Santo Araújo; Ana Lucia Tavares Gomes; Alfred Sholl-Franco; Adriana da Cunha Faria Melibeu; Claudio Alberto Serfaty; Paula Campello-Costa
Journal:  Neurosci Lett       Date:  2010-04-18       Impact factor: 3.046

Review 8.  GAP-43: an intrinsic determinant of neuronal development and plasticity.

Authors:  L I Benowitz; A Routtenberg
Journal:  Trends Neurosci       Date:  1997-02       Impact factor: 13.837

9.  Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase.

Authors:  Gregory J Finn; Bernadette S Creaven; Denise A Egan
Journal:  Biochem Pharmacol       Date:  2004-05-01       Impact factor: 5.858

10.  Binding of the bioactive component daphnetin to human serum albumin demonstrated using tryptophan fluorescence quenching.

Authors:  Jiaqin Liu; Jianniao Tian; Ying Li; Xiaojun Yao; Zhide Hu; Xingguo Chen
Journal:  Macromol Biosci       Date:  2004-05-17       Impact factor: 4.979

View more
  1 in total

Review 1.  Current Status of Therapeutic Approaches against Peripheral Nerve Injuries: A Detailed Story from Injury to Recovery.

Authors:  Ghulam Hussain; Jing Wang; Azhar Rasul; Haseeb Anwar; Muhammad Qasim; Shamaila Zafar; Nimra Aziz; Aroona Razzaq; Rashad Hussain; Jose-Luis Gonzalez de Aguilar; Tao Sun
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.